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Abstract  
Acquired uniparental disomy (aUPD) is a common finding in myeloid malignancies and 
typically acts to convert a somatically-acquired heterozygous mutation to homozygosity. We 
sought to identify the target of chromosome 14 aUPD (aUPD14), a recurrent abnormality in 
myeloid neoplasms and population cohorts of elderly individuals. We identified 29 cases 
with aUPD14q that defined a minimal affected region (MAR) of 11.2Mb running from 
14q32.12 to the telomere. Exome sequencing (n=7) did not identify recurrently mutated 
genes, but methylation-specific PCR at the imprinted MEG3-DLK1 locus located within the 
MAR demonstrated loss of maternal chromosome 14 and gain of paternal chromosome 14 
(p<0.0001), with the degree of methylation imbalance correlating with the level of aUPD 
(r=0.76; p=0.0001). The absence of driver gene mutations in the exomes of 3 individuals 
with aUPD14q but no known haematological disorder suggests that aUPD14q may be 
sufficient to drive clonal hemopoiesis. Analysis of cases with both aUPD14q and JAK2 V617F 
(n=11) indicated that aUPD14q may be an early event in some cases but a late event in 
others. We conclude that aUPD14q is a recurrent abnormality that targets an imprinted 
locus and may promote clonal hemopoiesis either as an initiating event or as a secondary 
change.  
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Introduction  
 
Uniparental disomy (UPD) refers to the situation in which both copies of a chromosome pair 
or parts of chromosomes have originated from one parent. Constitutional UPD is associated 
with developmental disorders caused by the abnormal expression of imprinted genes, i.e. 
genes that are differentially expressed depending on whether they have been maternally or 
paternally inherited. By contrast, somatically acquired UPD (aUPD) in cancer is a mechanism 
by which a pre-existing driver mutation (usually somatically acquired) is converted to 
homozygosity, thereby providing an additional clonal advantage. aUPD may involve whole 
chromosomes as a result of non-disjunction or, more commonly, whole chromosome arms 
or terminal segments as a consequence of mitotic recombination. aUPD cannot be detected 
by conventional cytogenetics but is readily apparent by the finding of somatically acquired 
long homozygous tracts without change in copy number by genome wide single nucleotide 
polymorphism (SNP) analysis.1 
 
aUPD is prevalent in myeloid neoplasms: chromosomes 4q, 7q, 9p, 11q and 13q are 
commonly affected and target mutated TET2, EZH2, JAK2, CBL and FLT3, respectively.1 
Several other regions of recurrent aUPD have been identified for which the target is 
unknown, e.g. chromosome 14q aUPD (aUPD14q) is seen in myeloid neoplasms2 and is one 
of the most common abnormalities associated with clonal hemopoiesis in population 
cohorts of elderly individuals.3,4 Here we show an unexpected and highly significant parental 
bias associated with aUPD14q, implicating an imprinted locus at 14q32 as the primary target 
rather than a specific mutated gene. 
 
Methods 
Study cohorts. Our study comprised two major groups of individuals, (i) patients diagnosed 
with a myeloproliferative neoplasm (MPN) or myelodysplastic/myeloproliferative neoplasm 
(MDS/MPN) according to standard morphological, hematologic and laboratory criteria; (ii) 
population cohorts of elderly individuals from Sweden, specifically the Uppsala Longitudinal 
Study of Adult Men (ULSAM)5 and the Prospective Investigation of the Vasculature in 
Uppsala Seniors (PIVUS).6 The study was approved by the following ethics committees or 
review boards: National Research Ethics Service (UK) Committee South West, Uppsala 
©    2015 Macmillan Publishers Limited. All rights reserved.
4 
 
Regional Ethical Review Board, Ethics Committee of the Biomedical Research Foundation of 
the Academy of Athens, Comitato Etico, Azienda Ospedaliero-Universitaria Careggi, Firenze. 
Informed consent obtained according to the Declaration of Helsinki. 
 
Molecular analysis. Genome wide SNP profiles for MPN and MDS/MPN cases, most of which 
have been published previously,2,7 were obtained from peripheral blood or bone marrow 
leucocyte DNA using the Affymetrix SNP 6.0 or Illumina Human OmniExpressExome v1.2 
platforms. Peripheral blood leucocyte profiles for the Swedish population cohorts were 
obtained using Illumina 2.5M HumanOmni arrays have also been published.8 Exome 
sequencing for MPN and MDS/MPN cases was performed using the Agilent SureSelect kit 
(Human All Exon 50 Mb) and sequenced using an Illumina HiSeq 2000 at the Wellcome Trust 
Centre for Human Genetics at Oxford, UK. Exome sequencing for the Swedish cases was 
performed by SciLifeLab, Stockholm. 
 
For methylation analysis, DNA was bisulphited (Zymo Research, Ervine, CA) alongside four 
healthy controls, amplified using forward primers specific for methylated or unmethylated 
MEG3 or NHP2L1 with a common FAM labelled reverse primer and analysed with a 3130xl 
Genetic Analyser (Applied Biosystems) as described.9 Loss of heterozygosity analysis at 
14q32 was performed using microsatellites D14S553, D14S267, D14S1006, D14S542, 
D14S292, D14S1007, again using a 3130xl Genetic Analyser. All primer sequences are listed 
in Supplementary Table 1.  
 
SNP array analysis. 
Array analysis was performed as described.7,10,11 For each SNP the log R Ratio (LRR), a 
measure of normalized total signal intensity, and B Allele Frequency (BAF), a measure of 
normalized allelic intensity ratio, was determined using the BeadStudio and pennCNV12 
software for Illumina and Affymetrix arrays respectively. Regions of aUPD were identified by 
BAF segmentation10 which excluded non-informative SNPs (SNPs with BAF >0.9 or BAF <0.1 
and SNPs where the absolute difference in BAF between preceding or succeeding SNPs is 
>0.6), mirrored BAF at 0.5 (mBAF), and used circular binary segmentation (CBS) to identify 
regions with similar allelic proportions. For heterozygous SNPs, the B-allele frequency (BAF) 
is the proportion of the total signal (A+B) accounted for by one allele (B). In a mixed 
©    2015 Macmillan Publishers Limited. All rights reserved.
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population of cells, the segmented mBAF value will be a combination of values of 1 and 0.5 
for cells with and without aUPD, respectively. Regions of aUPD were therefore defined as a 
region of allelic imbalance (segmented mBAF >0.56) with neutral copy number (log R ratio 
~0) that extended to the telomere. 12 For samples with known JAK2 V617F levels, 
determined by pyrosequencing,13 and BAF for both aUPD9p and aUPD14q aUPD, we were 
able to calculate both the proportion of cells with aUPD14 and the proportion of cells which 
were homozygous or heterozygous for JAK2 V617F. This allowed us to infer the order of 
acquisition of aUPD14 and JAK2 V617F (see Supplementary Table 2 for detailed 
calculations). 
 
Sequence analysis 
Analysis of exome sequencing data was as previously described.14 On average, the targeted 
exome of chromosome 14 was sequenced to a depth of 179x and 94.3% of the target bases 
were covered by at least 20 reads (Supplementary Table 3). For variants passing quality 
control (read depth ≥4, alternate read depth ≥2phred scaled quality ≥20, phred scaled base 
call accuracy ≥10, strand bias P≥0.0001, base quality bias P≥1e-100, tail bias P≥0.0001, and 
HWE P≥0.0001.) variant allele frequencies were used to approximate BAF and were 
analysed accordingly to identify regions of aUPD. A minimally affected region was identified 
in patient E5364 (chr14:94,245,652-qter) and interrogated in all aUPD14q exomes for rare 
variants that were either novel or had a minor allele frequency of 1% or less in databases of 
common variation (1000 genomes, Complete Genomics, Exome Variant Server). 
 
Results  
Prevalence of aUPD14q. We analysed in house array data on cases with myeloproliferative 
neoplasms (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and 
identified aUPD14q extending to the 14q telomere in 25 cases. Of the UK cases (n=21), 
1/293 (0.3%) had MDS/MPN, 8/563 (1.6%) had JAK2 V617F negative MPN (7 CALR mutated; 
1 MPL mutated) and 12/1054 (1.1%) had JAK2 V617F positive MPN, an overall prevalence 
similar to that identified in other studies of myeloid neoplasms (8/498; 1.6%).2,7,15-17. 
Trisomy chromosome 14 (+14) was seen in 4/293 (1.4%) MDS/MPN cases.2 Of the 1641 
individuals ≥70 years of age in the Swedish population-based cohorts, 4 (0.2%) had 
aUPD14,8 similar to the frequency in elderly individuals reported by other larger studies of 
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cases recruited for a variety of genome-wide association studies (GWAS).3,4  Cases with 
aUPD14q or other chromosome 14 abnormalities in our study are summarised on Table 1. 
 
Minimally affected region. The region affected by aUPD14q was variable between 
individuals and there was no difference between cases diagnosed with a hematological 
malignancy and those picked up in population based screens (Figure 1) Since the boundary 
of our smallest region of aUPD14q, case G_3499, was only defined to the nearest Mb, our 
minimally affected region was conservatively defined by case E5364 as 11.2Mb running 
from 14q32.12 to the telomere (chr14: 94,245,652-105,417,313). The MAR in previously 
published analyses of GWAS data was similar: 7.4Mb (chr14: 98,962,371-qter)4 and 6.9Mb 
(chr14: 99,425,044-qter).3 This region does not include FANCM, a variant of which was 
associated with aUPD14q in a single case.18 
 
Exome sequencing. Initially, with the aim of identifying a recurrently mutated 14q gene, we 
sequenced the whole exomes of cases with aUPD14q (n=7) or +14 (n=1). We focused on the 
identification of novel variants in the minimal region of aUPDq (chr14: 94,245,652-qter), 
thus capturing both constitutional and somatic mutations that might provide a selective 
advantage when reduced to homozygosity. No gene was identified with likely causative 
variants in more than one individual (Supplementary Table 3). In addition no rare variants 
were identified in FANCM which falls outside our MAR. Although it is possible that a target 
gene might have been missed due to inadequate coverage or mutational complexity, we 
considered an alternative explanation. 
 
Methylation bias associated with aUPD14q. Constitutional maternal UPD14q causes Temple 
syndrome whereas paternal UPD14q causes Kagami-Ogata syndrome. Both are 
developmental conditions resulting from aberrant expression of genes in the imprinted 
DLK1-MEG3 domain at 14q32. DLK1-MEG3 is the only known imprinted locus on 
chromosome 14 and is retained in the aUPD14q MAR defined above. To test if DLK1-MEG3 
might be targeted by chromosome 14 abnormalities, we determined the MEG3 methylation 
status of cases with aUPD14q (n=22) or +14 (n=6; Table 1). MEG3 is methylated on the 
paternally inherited chromosome 14 but is unmethylated when maternally inherited. An 
increase in methylation therefore indicates paternal aUPD14q, i.e. gain of the region 
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containing MEG3 from the paternal chromosome 14 and loss of the corresponding region 
from the maternal chromosome 14 (Figure 2). Samples from cases with aUPD14q showed a 
striking increase in methylation (mean methylation value 0.24, SD +/- 0.17) compared to 
healthy controls (n=24; mean methylated value 0.00, SD +/- 0.04) consistent with paternal 
aUPD (Figure 2A-B; Mann Whitney U test, p<0.0001). Methylation values and BAF in the 
region of aUPD14q were strongly correlated (Spearman’s rank correlation, r=0.76, p=0.0001) 
(Figure 2) suggesting that the relatively low levels of methylation imbalance in some 
individuals was due to the presence of a small clone with aUPD14q. In contrast, methylation 
in the +14 cases showed no parental bias (mean methylation value 0.05, SD +/- 0.17; +14 
cases vs. controls, p=0.34, Mann Whitney U test). This is the first time to our knowledge that 
aUPD has been associated with a specific parent of origin effect, a finding that indicates 
aUPD14q targets an imprinted locus. 
 
Methylation bias is specific for aUPD14q. To determine if a parent of origin effect is seen in 
other regions of aUPD, we analysed MDS/MPN cases with aUPD22q (n=5), an abnormality 
that is also seen recurrently in myeloid malignancies and population cohorts of elderly 
individuals. Like aUPD14q, the target of aUPD22q has not been identified but there is a 
candidate imprinted locus (NHP2L1) within the affected region.19 Methylation analysis 
indicated maternal aUPD22q in two cases and paternal aUPD22q in three cases 
(Supplementary Figure 1). Although the number of cases is small, the findings clearly 
indicate no parent of origin effect, supporting the notion that the imbalance observed for 
aUPD14q is likely to be pathogenetically relevant.  
 
Methylation bias in cases without aUPD14q. To determine if 14q imprinting abnormalities 
are more widespread in myeloid neoplasia, MEG3 methylation status was examined in 
additional MDS/MPN cases (n=96) that had either been analysed by SNP arrays and were 
known to be negative for aUPD14q (n=48) or were randomly selected without knowledge of 
their aUPD14 status (n=48). Most cases had methylation levels that were indistinguishable 
from healthy controls, but three had a clear gain of methylation (Figure 2B). All three were 
of unknown aUPD14q status and so we tested six microsatellite loci at 14q32: only one case 
was homozygous at all 6 loci suggesting that gain of methylation in the remaining two cases 
had arisen by a mechanism other than aUPD14q (Supplementary Table 4) . 
©    2015 Macmillan Publishers Limited. All rights reserved.
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EZH2 mutations in some cases with aUPD14q. MEG3 and other transcripts within the MEG3-
DLK1 locus have been implicated in regulation of the polycomb repressive complex 2 
(PRC2),20 components of which are recurrently inactivated in myeloid neoplasia by mutation 
of EZH2, SUZ12 or EED.2,21 It is possible therefore that the consequence of aUPD14q might 
be functional inactivation of PRC2, in which case we would expect aUPD14q and PRC2 
mutations to be mutually exclusive. Partial sequence analysis of EZH2 and SUZ12, the most 
commonly mutated components of PRC2, revealed causative EZH2 mutations in 2/8 
aUPD14q cases (Supplementary Table 5) which suggests that functional inactivation of PRC2 
is unlikely to be the primary consequence of aUPD14. 
 
aUPD14q may be an early or late event. Inspection of the exome sequencing data for the 
aUPD14q cases (n=7) revealed no other obvious driver mutations in 3/4 individuals from the 
population cohorts, suggesting that aUPD14q alone may be sufficient to promote clonal 
hemopoiesis. The fourth individual (PIVUS 931) was positive for JAK2 V617F as well as a 
TP53 mutation; he was subsequently diagnosed with polycythemia vera following 
recruitment into the PIVUS study. In contrast, all 3 cases with diagnosed myeloid malignancy 
that were exome sequenced had additional somatic driver mutations in SF3B1, EZH2, JAK2 
or TET2 (Table 1). 
 
Of the aUPD14q cases that were positive for JAK2 V617F, information on the mutation level 
as well as the BAF for 9p and 14q aUPD was available for eleven individuals. For these we 
were able to estimate both the proportion of cells with aUPD14q and the proportion of cells 
which were homozygous or heterozygous for JAK2 V617F (Figure 3). This in turn enabled us 
to infer whether aUPD14q or JAK2 V617F was likely to have arisen first. Assuming that JAK2 
V617F and aUPD14q arose within the same clone, our findings suggest that aUPD14q arose 
before JAK2 V617F in cases E09853, PT1645, PT1670, PT1876 since the proportion of cells 
positive for aUPD14q was 2-fold or more higher than the proportion positive for the JAK2 
mutation. In contrast, JAK2 V617F is likely to have arisen first in cases E09861, H3589_11, 
H10872_10, W1212280 H131_12 and E09984. The order is uncertain for case E09895.  It is 
notable therefore that aUPD14q arose first in 3/4 cases with essential thrombocythemia but 
only 1/7 cases of polycythemia vera. 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Discussion 
 
Developmental abnormalities arising from constitutional UPD result from inappropriate 
expression of imprinted genes. Inherited maternal UPD14q is associated with Temple 
Syndrome, characterized by low birth weight, hypotonia, motor delay, early onset of 
puberty and short adult stature.22 Inherited paternal UPD14q is associated with Kagami-
Ogata syndrome, characterized by severe developmental delay, hepatoblastoma and 
characteristic dysmorphology.23 Both abnormalities result from aberrant expression of the 
the DLK1-MEG3 domain at 14q32, a large and complex imprinted cluster of genes and non-
coding RNAs. The methylated paternally derived chromosome expresses the protein-coding 
genes DLK1, RTL1 and DIO3 whilst the non-methylated maternally derived chromosome 
expresses the non-coding genes MEG3, MEG8, asRTL1, multiple miRNAs and snoRNAs.24 It is 
not known whether the observed clinical phenotypes are caused aberrant expression of an 
individual gene, individual non-coding RNAs or a combination of factors. 
 
Our finding of a highly significant parent of origin effect associated with aUPD14q strongly 
implicates an imprinted locus as the primary target, and that paternal homozygosity for this 
target provides a growth advantage over cells that harbor both alleles. Del(20q), another 
somatic abnormality associated with myeloid neoplasms, has been shown to target an 
imprinted gene cluster25 but this is the first time to our knowledge that aUPD has been 
associated with an imprinted target. Although we cannot exclude the possibility that 
aUPD14q might target another imprinted locus at 14q32, we believe it is highly likely that 
the true target is DLK1-MEG3 since (i) this cluster falls with the 11.2Mb MAR, an interval 
that contains 121 known protein-coding genes plus the immunoglobulin region, and (ii) 
despite extensive searches there are no other confirmed imprinted loci within the MAR, or 
indeed elsewhere on chromosome 14. Furthermore, expression of DLK1-MEG3 has been 
reported to be deregulated in diverse neoplasms in the absence of chromosome 14 
abnormalities, including acute promyelocytic leukemia26,27 and myelofibrosis.28,29 In our 
study we did not have suitably stored material for expression analysis of aUPD14q cases, 
however expression analysis alone is unlikely to be informative since by definition aUPD 
would be expected to distort the normal expression of imprinted genes in the affected 
region whether they were of pathogenetic relevance or not. 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Of the 22 aUPD14q cases analysed for MEG3 methylation in our study, 21 had positive 
values indicative of paternal aUPD. One case had a negative methylation value. We do not 
have an explanation for this aberrant case, but potentially other mutations may have been 
present that promoted clonal expansion. We note that aUPD for other regions has not been 
associated with a specific mutational target in all cases, e.g. in we found that only 9 of 12 
MDS/MPN cases with aUPD7q had EZH2 mutations, with the target of the remaining 3 cases 
remaining unclear.2 
 
Similar to other mutations associated with clonal hemopoiesis in population cohorts,30,31 
aUPD14q is more prevalent in the elderly. Previous studies found aUPD14q in 21/50,222 
(0.04%) individuals, rising to 14/15,101 (0.09%) in those >60 years of age,3,4 an increase that 
parallels the increase in myeloid neoplasia seen in the elderly. Analysis of longitudinal data 
estimated a 10-fold elevated risk of developing a hematological malignancy for individuals 
with any acquired chromosome anomaly,4 and a similar risk was estimated for individuals 
with somatic mutations in genes known to be associated with myeloid malignancies.30,31 The 
most commonly mutated genes in population cohorts were DNMT3A, TET2 and ASXL1, and 
the finding that most individuals had only a single abnormality suggested that mutations in 
these genes are often initiating events for clonal hemopoiesis. Inspection of our exome 
sequencing data for the aUPD14q cases revealed no mutations in known driver genes in 3/4 
population cohort cases. By contrast, all 3 cases with diagnosed myeloid malignancy had 
additional somatic driver mutations. We suggest therefore that aUPD14q may also initiate 
clonal hemopoiesis and predispose to overt malignancy. However when we examined cases 
that had both aUPD14q and JAK2 V617F, it was clear that aUPD14q may be an early event in 
some MPN cases but a late event in others. Furthermore, we found that aUPD14q tends to 
arise before JAK2 V617F in essential thrombocythaemia but after V617F in polycythemia 
vera. This is reminiscent of the finding that mutated TET2 may precede or follow the 
acquisition of JAK2 V617F in MPN, with the order of acquisition influencing clinical features 
and stem cell biology.32  
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Figure Legends 
 
Figure 1: Extent of aUPD14q in the 29 cases, indicating the minimally affected region and 
location of DLK1-MEG3.  
 
Figure 2. MEG3 methylation analysis. (A) PCR of bisulphited DNA allowed differential 
amplification and relative quantification of the methylated (paternal) and unmethylated 
(maternal) alleles. Control samples show approximately equal paternal and maternal peaks 
sizes whereas samples with a high level of aUPD14 show complete loss of the maternal 
allele. Methylation values are calculated as the methylated paternal allele peak height 
divided by the sum of methylated and unmethylated peaks, with control values normalized 
to zero. Complete loss of the maternal allele and gain of the paternal allele in cases is seen 
in cases with aUPD14q in the great majority of cells and is indicated by a methylation value 
of 0.5. In many cases, aUPD14q is only seen in a proportion of cells, as indicated by the SNP 
array BAF in the affected region. Consequently the methylation value ranges between 0 and 
0.5 for paternal gain/maternal loss and between 0 and -0.5 for paternal loss/maternal gain. 
(B) Methylation values for healthy controls (n=24), cases with aUPD14q (n=22), trisomy 14 
(n=6), randomly selected MDS/MPN cases without knowledge of their aUPD14q status 
(n=48) and MDS/MPN cases that were known to be negative for aUPD14q or other visible 
chromosome 14 abnormalities (n=48). The results show a highly significant skewing 
(p<0.0001 Mann-Whitney U test) in the aUPD14q cases towards paternal aUPD. (C) Graph 
illustrating the strong correlation between the methylation value and mean aUPD BAF for 
each case.  
 
Figure 3. Proportions of cells positive for JAK2 V617F and aUPD14q in cases with both 
abnormalities. Black bars indicate cells positive for aUPD14q; grey bars indicate homozygous 
JAK2 V617F mutant cells and white bars indicate heterozygous JAK2 V617F mutant cells.  
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Table 1: Summary of cases with chromosome 14 abnormalities  
 
Patient 
identifier 
aUPD14q region or karyotype 
(hg19 co-ordinates) 
aUPD14q 
size (Mb) 
Disorder Exome  Driver mutations Mean B-allele 
frequency of 
aUPD14q region 
Methylation 
level 
a
 
E7173 chr14: 70924501-105930406 35.0 ET Yes SF3B1 K700E 0.81 0.45 
E5364 chr14: 94245652-105417313 11.2 CMML Yes EZH2 exon9:c.729-2A>- 0.91 0.49 
E6459 chr14: 33291583-105930406 72.6 PMF Yes JAK2 V617F; TET2 D1242V 0.73 0.52 
PT03B08 chr14:20211644-107285437 87.1 PMF  CALR Type 2 0.82 0.28 
CB44 chr14:22053729-107285437 85.2 ET  CALR Type 1 0.74 0.05 
PT02B05 chr14:73672831-107274052 33.6 ET  MPL W515K 0.8 0.25 
PT02E11 chr14:23582569-107220898 83.6 ET  CALR Type 2 0.8 0.27 
AN804 chr14:21240673-107285437 86.0 PMF  CALR Type 1 0.80 0.32 
11_4629 chr14:21209871-107287663 86.1 ET  CALR Type 2 0.71 0.21 
E6430 chr14:23102969-107274052 84.2 ET  CALR Type 1 0.64 0.12 
E09853 chr14:20213937-107274052 87.1 PV  JAK2 V617F 0.62 -0.10 
E09861 chr14:20295510-107274052 87.0 PV  JAK2 V617F 0.77 0.19 
E09895 chr14:56103882-107287663 51.1 PV  JAK2 V617F 0.71 0.22 
E09984 chr14:50192257-107287663 57.1 ET  JAK2 V617F 0.79 0.31 
H3589_11 chr14:59183573-107287663 48.1 PV  JAK2 V617F 0.58 0.07 
H10872_10 chr14:24653187-107222493 82.6 PV  JAK2 V617F 0.58 0.12 
W1212280 chr14:24843620-107287663 82.4 PV  JAK2 V617F 0.57 0.07 
H131_12 chr14:92280675-107274052 15.0 PV  JAK2 V617F 0.63 0.07 
PT1544 chr14: 94238353- 107287663 13.0 ET  CALR Type 2 0.69 ND 
PT1645 chr14: 21070264- 105965102 84.9 ET  JAK2 V617F 0.89 ND 
PT1670 chr14: 23248583- 107287663 84.0 ET  JAK2 V617F 0.79 ND 
PT1876 chr14: 72220169- 107231967 35.0 ET  JAK2 V617F 0.89 ND 
G_735 chr14:27349540-107349540 80
b 
PMF  JAK2 V617F NA 0.40 
G_3358 chr14:83349540-107349540 24
b 
PMF  JAK2 V617F NA 0.52 
G_3499 chr14:101250540-107349540 6
b 
PMF  JAK2 V617F NA 0.19 
ULSAM 546 chr14:24944467-107349540 82.4 PC Yes None detected 0.69 0.07 
ULSAM 831 chr14:40334000-107349540 67.0 PC Yes None detected 0.67 ND 
PIVUS 931 chr14:94156220-107331190 13.2 PC Yes JAK2 V617F; TP53 exon6:c.376-2A>G 0.77 ND 
PIVUS 892 chr14:77435975-107349540 29.9 PC Yes None detected 0.61 ND 
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E4051 +14  aCML Yes   0.15 
E6901 +14  CMML    -0.14 
W813483 46,XX,?dup(12)(p11p12),idic(14
) (p11)/47,idem,+idic(14) 
 AML    0.29 
W1301891 47,XX,+14[20]  MDS    0.12 
W1407109 46,XX,del(5)(q13q33)[1]/58,sl,+
1,+2,+del(5),+8,+9,+10,+11,+13,
+14,+19,+21,+22[9]/60,sdl1,+6,
add(6)(q1),+mar[2] 
 MDS    0.11 
W1409489 45,X,-
Y[6]/46,idem,+14[8]/46,XY[6] 
 MDS    -0.13 
E7820 aUPD14q by microsatellite 
analysis 
 CMML  EZH2 C590F   
 
CMML: chronic myelomonocytic leukemia; aCML: atypical chronic myeloid leukemia; AML: acute myeloid leukemia; ET: essential thrombocythemia; PMF: primary 
myelofibrosis; PC: cases from Swedish elderly population-based cohorts with no hematological malignancy diagnosed at the time of sampling (PIVUS 931 was subsequently 
diagnosed with polycythemia vera). 
a
Paternal chromosome loss or gain is given by the methylated (paternal) peak height divided by the sum of methylated and unmethylated peaks, normalized to shift control 
values to zero. A positive value indicates methylation (paternal chromosome) gain compared with controls. 
b
Regions of aUPD14q only defined to the nearest megabase, the minimally affected region of aUPD14q was therefore conservatively defined by case E5364 as 11.2 Mb, 
chr14: 94245652-qter. 
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